Spots Global Cancer Trial Database for A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa
Official Title: An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa
Study ID: NCT01000740
Conditions
Study Description
Brief Summary: The primary objective is to describe the quality of life of long-term survivors who are not terminated from the EAP.
Detailed Description:
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Beijing, Beijing, China
Research Site, Guangzhou, Guangdong, China
Research Site, Wuhan, Hubei, China
Research Site, Nanjing, Jiangsu, China
Research Site, Suzhou, Jiangsu, China
Research Site, Jinan, Shandong, China
Research Site, Shanghai, Shanghai, China
Research Site, Chengdu, Sichuan, China
Research Site, Hangzhou, Zhejiang, China
Contact Details
Name: Karen Atkin
Affiliation: AstraZeneca
Role: STUDY_DIRECTOR
Name: Louis Zhang
Affiliation: AstraZeneca
Role: STUDY_CHAIR
Name: Longyun Li
Affiliation: Peking Union Medical College Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
